Patient and graft characteristics of 128 recipients of myeloablative double-unit CBT (n = 256 units)
| Characteristics . | Value . |
|---|---|
| Median age, years (range) | 35 (0.9-69) |
| Children younger than 16 years | 31 (24%) |
| Median weight, kg (range) | 68 (8-116) |
| N (%) AML* | 60 (47%) |
| N (%) ALL† | 33 (26%) |
| N (%) MDS/MPD | 10 (8%) |
| N (%) NHL/CLL/HL | 25 (19%) |
| N (%) CMV serostatus of recipient | |
| Negative | 58 (45%) |
| Positive | 70 (55%) |
| N (%) conditioning intensity | |
| High-dose myeloablative‡ | 65 (51%) |
| Reduced intensity§ | 63 (49%) |
| Median infused TNC × 107/kg (range) | |
| Larger unit (n = 128) | 2.85 (1.46-12.79) |
| Smaller unit (n = 128) | 2.01 (0.91-7.09) |
| Median infused viable CD34+ cells × 105/kg (range) | |
| Larger unit (n = 128) | 1.30 (0.26-6.97) |
| Smaller unit (n = 128) | 0.68 (0.08-2.12) |
| N (%) cord unit-recipient HLA-A, -B, antigen, -DRB1 allele match¶ | |
| 6/6 | 12 (5%) |
| 5/6 | 118 (46%) |
| 4/6 | 126 (49%) |
| N (%) donor-recipient HLA-A, -B, -C, -DRB1, -DQB1 allele match¶ | |
| 8-10/10 | 46 (18%) |
| 6-7/10 | 102 (40%) |
| 2-5/10 | 108 (42%) |
| Characteristics . | Value . |
|---|---|
| Median age, years (range) | 35 (0.9-69) |
| Children younger than 16 years | 31 (24%) |
| Median weight, kg (range) | 68 (8-116) |
| N (%) AML* | 60 (47%) |
| N (%) ALL† | 33 (26%) |
| N (%) MDS/MPD | 10 (8%) |
| N (%) NHL/CLL/HL | 25 (19%) |
| N (%) CMV serostatus of recipient | |
| Negative | 58 (45%) |
| Positive | 70 (55%) |
| N (%) conditioning intensity | |
| High-dose myeloablative‡ | 65 (51%) |
| Reduced intensity§ | 63 (49%) |
| Median infused TNC × 107/kg (range) | |
| Larger unit (n = 128) | 2.85 (1.46-12.79) |
| Smaller unit (n = 128) | 2.01 (0.91-7.09) |
| Median infused viable CD34+ cells × 105/kg (range) | |
| Larger unit (n = 128) | 1.30 (0.26-6.97) |
| Smaller unit (n = 128) | 0.68 (0.08-2.12) |
| N (%) cord unit-recipient HLA-A, -B, antigen, -DRB1 allele match¶ | |
| 6/6 | 12 (5%) |
| 5/6 | 118 (46%) |
| 4/6 | 126 (49%) |
| N (%) donor-recipient HLA-A, -B, -C, -DRB1, -DQB1 allele match¶ | |
| 8-10/10 | 46 (18%) |
| 6-7/10 | 102 (40%) |
| 2-5/10 | 108 (42%) |
Of the 129 patient cohort, 1 died early without identification of a dominant unit and was excluded from further analysis. AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; NHL, non-Hodgkin lymphoma.
Includes 33 patients in first complete remission (CR1), 24 in CR2, 2 in CR3, and 1 in aplasia after chemotherapy.
Includes 19 patients in CR1, 8 in CR2, 5 in CR3, and 1 in CR4.
Includes 48 patients who received cyclophosphamide 120/fludarabine 75/total body irradiation 1320 to 1375; 11 patients who received clofarabine/melphalan/thiotepa, and 6 who received other regimens.
Regimens that were reduced intensity but functionally myeloablative including 55 patients who received cyclophosphamide 50/fludarabine 150/thiotepa 10/total body irradiation 400, and 8 heavily pretreated patients who received fludarabine 150/melphalan 140.
Reflects all 256 CB units infused.